Nova/Univ. of Minnesota agreement
Executive Summary
Nova announced Oct. 31 that it has secured exclusive worldwide rights to a series of opiate compounds developed by the University of Minnesota which Nova said offer potential for treatment of common gastrointestinal problems such as constipation, diarrhea and spasticity of the colon.